A client with non-Hodgkin lymphoma has been receiving rituxi…
A client with non-Hodgkin lymphoma has been receiving rituximab therapy for several treatment cycles. During a routine evaluation, the nurse reviews the client’s complete blood count with differential and metabolic panel to assess for therapy-related complications. Which laboratory finding requires immediate follow-up by the nurse due to the risk of life-threatening complications associated with rituximab?